Table 3. Impact of chemotherapy delay beyond 7 days by IDH1/2 mutations status in Cox multivariate regression analysis.
| Variables | HR(95%CI) | P value |
|---|---|---|
| Age | 1.02(1.004,1.03) | 0.008 |
| WBC | 1.003(1.001,1.005) | 0.001 |
| DNMT3a | 1.75(1.16,2.65) | 0.008 |
| NPM1 | 0.81(0.56,1.18) | 0.278 |
| FLT3ITD | 1.15(0.73,1.82) | 0.537 |
| CEBPA DM | 0.11(0.03,0.44) | 0.002 |
| Cytogenetic risk group | ||
| Intermediate vs. Favorable | 2.21(1.14,4.29) | 0.020 |
| Adverse vs. Favorable | 2.71(1.24,5.94) | 0.013 |
| IDHm&Day7 vs. IDHm&Day6 | 2.06(1.16,3.65) | 0.014 |
| IDHw&Day6 vs. IDHm&Day6 | 1.17(0.71,1.91) | 0.533 |
| IDHw&Day7 vs. IDHm&Day6 | 1.50(0.88,2.57) | 0.140 |
WBC: white blood cell counts. DM: double-allele. IDHm&Day6: IDH1/2 mutations and treatment within 6 days; IDHm&Day7: IDH1/2 mutations and treatment delay 7 days or more; IDHw&Day6: IDH1/2 wildtype and treatment within 6 days; IDHw&Day7: IDH1/2 wildtype and treatment delay 7 days or more.